Abstract is: Health Economics, Policy and Law is a quarterly peer-reviewed scientific journal covering health economics, policy, and law. It was established in 2006 and is published by Cambridge University Press. The editor-in-chief is Adam Oliver (London School of Economics). According to the Journal Citation Reports, the journal has a 2016 impact factor of 1.675, ranking it 37th out of 77 journals in the category "Health Policy & Services".
| scientific journal | Q5633421 |
| P6981 | ACNP journal ID | 2435420 |
| 2434443 | ||
| P8375 | Crossref journal ID | 52559 |
| P1250 | Danish Bibliometric Research Indicator (BFI) SNO/CNO | 1961 |
| P1058 | ERA Journal ID | 32874 |
| P2671 | Google Knowledge Graph ID | /g/11hb7f320n |
| P8903 | HAL journal ID | 13826 |
| P236 | ISSN | 1744-1331 |
| 1744-134X | ||
| P7363 | ISSN-L | 1744-1331 |
| P1277 | JUFO ID | 56915 |
| P4730 | Mir@bel journal ID | 2337 |
| P1055 | NLM Unique ID | 101247224 |
| P243 | OCLC control number | 63797833 |
| P856 | official website | http://www.cambridge.org/uk/journals/journal_catalogue.asp?mnemonic=HEP |
| https://www.cambridge.org/core/journals/health-economics-policy-and-law | ||
| P10283 | OpenAlex ID | V78689143 |
| P3181 | OpenCitations bibliographic resource ID | 23039 |
| P7662 | Scilit journal ID | 2162578 |
| P1156 | Scopus source ID | 10900153303 |
| P1025 | SUDOC editions | 10475768X |
| 108068986 |
| P495 | country of origin | United Kingdom | Q145 |
| P1240 | Danish Bibliometric Research Indicator level | 1 | |
| P8875 | indexed in bibliographic review | Scopus | Q371467 |
| Social Sciences Citation Index | Q1090953 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | health economics | Q31218 |
| P123 | publisher | Cambridge University Press | Q912887 |
| P1476 | title | Health Economics, Policy and Law |
| Q47569792 | 'Fair innings' in the face of ageing and demographic change |
| Q47569802 | A European late starter: lessons from the history of reform in Irish health care. |
| Q45901716 | A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. |
| Q47447111 | A game theoretic model of drug launch in India |
| Q60721930 | A new approach to the comparative analysis of health systems: invasive treatment for heart disease in the US, France, and their two world cities |
| Q53818765 | A place in the sun? Healthcare rights of retired UK citizens in Spain post-Brexit. |
| Q87477454 | A reflection on Richard B. Saltman 'Structural patterns in Swedish health policy' |
| Q81657271 | A response to Birch and Gafni--some reasons to be cheerful about NICE |
| Q52633034 | A successful Charter challenge to medicare? Policy options for Canadian provincial governments. |
| Q98163777 | A tribute to the foot soldiers: European health agencies in the fight against antimicrobial resistance |
| Q81657298 | Academia, policy and politics |
| Q84517518 | Access and choice--competition under the roof of solidarity in German health care: an analysis of health policy reforms since 2004 |
| Q58345633 | Access as a policy-relevant concept in low- and middle-income countries |
| Q89573152 | Access to health care in post-apartheid South Africa: availability, affordability, acceptability |
| Q37383644 | Access to health care services--an English policy perspective |
| Q46924716 | Access to primary care in Hong Kong, Greater London and New York City. |
| Q60721806 | Access to psycho-social resources and health: exploratory findings from a survey of the French population |
| Q90560644 | Access to treatment and the constitutional right to health in Germany: a triumph of hope over evidence? |
| Q46029842 | Achieving sustainable universal health coverage in low- and middle-income countries. |
| Q81657331 | Acquisition and disclosure of genetic information under alternative policy regimes: an economic analysis |
| Q81657209 | Activity based financing in England: the need for continual refinement of payment by results |
| Q81657217 | Activity-based payments and reforms of the English hospital payment system |
| Q81657151 | Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards |
| Q90643876 | Addressing perceived economic obstacles to genetic testing as a way to mitigate disparities in family health history for adoptees |
| Q47360658 | Adopting new medical technologies in Russian hospitals: what causes inefficiency? (qualitative study). |
| Q48460419 | Adverse selection and moral hazard in the provision of clinical trial ancillary care |
| Q40069735 | Aging, health expenditure, proximity to death, and income in Finland |
| Q44891644 | Aging, social capital, and health care utilization in Canada |
| Q81657161 | Aid, truth, and policy: what do we know? |
| Q97595524 | Alternative provision of public health care: the role of citizens' satisfaction with public services and the social responsibility of government |
| Q98632654 | Alternative provision of public health care: the role of citizens' satisfaction with public services and the social responsibility of government - ERRATUM |
| Q44939832 | America's health care dilemma: not a pretty sight |
| Q87643466 | An Indian perspective on the challenges in global health financing |
| Q92994657 | An analysis of the development assistance for health (DAH) allocations for STD control in Africa |
| Q81968687 | An economic model of social capital and health |
| Q44637079 | An exploratory study of associations between social capital and self-assessed health in Norway |
| Q38090762 | Analytical perspectives on performance-based management: an outline of theoretical assumptions in the existing literature |
| Q98944180 | Answers in search of questions: What does the comparison of COVID19 data among Regions in Northern Italy tell us? |
| Q84208364 | Are health problems systemic? Politics of access and choice under Beveridge and Bismarck systems |
| Q37219008 | Are subjective well-being measures any better than decision utility measures? |
| Q96123173 | Assessing the potential impact on health of the UK's future relationship agreement with the EU: analysis of the negotiating positions |
| Q57462869 | Attitudes of health professionals concerning bedside rationing criteria: a survey from Portugal |
| Q45873077 | Avoiding another directive: the unstable politics of European Union cross-border health care law. |
| Q47236002 | Back to the future: 10 years of European health reforms |
| Q81657326 | Better regulation in troubled times |
| Q89110142 | Beyond the threshold |
| Q47552663 | Bitter pills: the impact of medicare on mental health |
| Q85776905 | Blurring the boundaries between public and private health care services as an alternative explanation for the emergence of black medicine: the Israeli case |
| Q37912286 | Breaking up is hard to do: the economic impact of provisional funding contingent upon evidence development. |
| Q98215980 | Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride? |
| Q102062637 | Can Asia provide models for tax-based European health systems? A comparative study of Singapore and Sweden |
| Q57140134 | Can a medical need clause help manage the growing costs of prescription drugs in the EU? |
| Q38132410 | Can all cause readmission policy improve quality or lower expenditures? A historical perspective on current initiatives |
| Q49686505 | Can history improve big bang health reform? Commentary |
| Q88587155 | Can universal access be achieved in a voluntary private health insurance market? Dutch private insurers caught between competing logics |
| Q57093802 | Canadian medicare: historical reflections, future directions |
| Q48278461 | Capacity and authority: comments on governing doctors and health care |
| Q85224500 | Care at the end of life. Introduction |
| Q128724423 | Carolyn Hughes Tuohy, Remaking Policy: Scale, Pace and Political Strategy in Health Care Reform. University of Toronto Press, Toronto 2018. p. 717 |
| Q96690175 | Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union |
| Q96950503 | Changes in the balance between formal and informal care supply in England between 2001 and 2011: evidence from census data |
| Q45055035 | Changes in the inequality of mental health: suicide in Australia, 1907-2003. |
| Q60670635 | Changing choices in health care: implications for equity, efficiency and cost |
| Q84485922 | Choice and competition in publicly funded health care |
| Q84720765 | Choice and privatisation in Swedish primary care |
| Q42985223 | Choice cuts: parsing policymakers' pursuit of patient empowerment from an individual perspective |
| Q39951149 | Choice experiments in health: the good, the bad, the ugly and toward a brighter future |
| Q39207269 | Choice of providers and mutual healthcare purchasers: can the English National Health Service learn from the Dutch reforms? |
| Q47235981 | Choice policies in Northern European health systems |
| Q89172695 | Clarifying the role of values in cost-effectiveness |
| Q37590420 | Co-payments in the NHS: an analysis of the normative arguments |
| Q84323995 | Coming into line: the EU's Court softens on cross-border health care |
| Q98944177 | Comment: Resilient Managed Competition during Pandemics: Lessons from the Italian experience |
| Q58666692 | Commentary 1: The ethics of licensing smokers |
| Q54518375 | Commentary 2: Criminalising the supply of tobacco. |
| Q41095917 | Commentary to Adam Oliver's 'Incentivising improvements in health care delivery'. |
| Q84420372 | Community rating in the absence of risk equalisation: lessons from the Irish private health insurance market |
| Q89141885 | Comparative analysis of health system performance in Montreal and New York: the importance of context for interpreting indicators |
| Q85224503 | Comparing the United States and United Kingdom: contrasts and correspondences |
| Q83901673 | Competition and compromise in negotiating the new governance of medical performance: the clinical governance and revalidation policies in the UK |
| Q50123916 | Competition in health care: lessons from the English experience |
| Q50503774 | Complementary logics of target-setting: hierarchist and experimentalist governance in the Scottish National Health Service. |
| Q93192503 | Conceptualising equity in the impact evaluation of chronic disease management programmes: a capabilities approach |
| Q81657314 | Conceptualizing decentralization in European health systems: a functional perspective |
| Q64928524 | Consumer-directed health care: promise or puffery? |
| Q47632225 | Contested evidence: a Dutch reimbursement decision taken to court |
| Q88220726 | Contested evidence: a Dutch reimbursement decision taken to court - CORRIGENDUM |
| Q44977786 | Contingent valuation studies and health policy |
| Q39473175 | Contingent valuation: has the debate begun? |
| Q37586543 | Contingent valuation: what needs to be done? |
| Q97634522 | Cooperation amongst insurers on enhancing quality of care: precondition or substitute for competition? |
| Q48200200 | Cooperation and conflict between very similar occupations: the case of anesthesia |
| Q56898361 | Coping accountably in a dangerous world |
| Q87350670 | Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use |
| Q95558223 | Cost-effectiveness thresholds: a comment on the commentaries |
| Q88460754 | Could local integration of health and social care finally overcome the pull to the centre? |
| Q50358234 | Courts and health care rationing: the case of the Brazilian Federal Supreme Court |
| Q57471072 | Coverage mandates and market dynamics: employer, insurer and patient responses to parity laws |
| Q47202364 | Creating a 'hostile environment for migrants': the British government's use of health service data to restrict immigration is a very bad idea |
| Q38978867 | Cross-national comparisons of human resources for health - what can we learn? |
| Q81657164 | Dealing with the medical axis-of-power: the case of Japan |
| Q43874762 | Decision making by NICE: examining the influences of evidence, process and context |
| Q81657178 | Defining hospital markets for antitrust enforcement: new approaches and their applicability to The Netherlands |
| Q86005231 | Delays in medical malpractice litigation in civil law jurisdictions: some evidence from the Italian Court of Cassation |
| Q85224512 | Delivering better end-of-life care in England: barriers to access for patients with a non-cancer diagnosis |
| Q90706958 | Demand-based models and market failure in health care: projecting shortages and surpluses in doctors and nurses |
| Q48369607 | Dementia, death and advance directives |
| Q36190993 | Democratic transitions, health institutions, and financial protection in the emerging economies: insights from Asia. |
| Q44179292 | Determinants of branded prescription medicine prices in OECD countries |
| Q48035894 | Determining what should be included in a publicly funded health care system: reflecting on 'Individual responsibility for what? A conceptual framework for exploring the suitability of private financing in a publicly funded health-care system'. |
| Q40069727 | Developing methods that really do value the 'Q' in the QALY. |
| Q30061773 | Development assistance for health: critiques, proposals and prospects for change |
| Q38404585 | Development assistance for health: what criteria do multi- and bilateral funders use? |
| Q48222856 | Disciplining health policy? Explaining health policy by reference to…what? |
| Q38404570 | Distributing development assistance for health: simulating the implications of 11 criteria |
| Q49820352 | Doctors as Stewards of medicare, or not: CAMSI, MRG, CDM, DRHC and the thin alphabet soup of physician support |
| Q39439272 | Does availability of informal care within the household impact hospitalisation? |
| Q53189661 | Does certificate of need law enhance competition in inpatient care market? An empirical analysis. |
| Q39898500 | Does competition among general practitioners increase or decrease the consumption of specialist health care? |
| Q56669836 | Does government expenditure reduce inequalities in infant mortality rates in low- and middle-income countries?: A time-series, ecological analysis of 48 countries from 1993 to 2013 |
| Q81657339 | Does greater Medicare HMO enrollment cause adverse selection into Medigap? |
| Q39140337 | Does history provide a short cut to futurology? |
| Q31163042 | Does it really matter where you live? A panel data multilevel analysis of Swedish municipality-level social capital on individual health-related quality of life |
| Q93020390 | Does managed competition constrain hospitals' contract prices? Evidence from the Netherlands |
| Q92420011 | Double-edged sword of federalism: variation in essential health benefits for mental health and substance use disorder coverage in states |
| Q45930116 | Dying of corruption |
| Q98632679 | EU health law and policy: shaping a future research agenda |
| Q81657279 | EU law and national health policies: problem or opportunity? |
| Q81657252 | EU law and regulation of private health insurance |
| Q98476869 | EU mental health governance and citizen participation: a global governmentality perspective |
| Q44299342 | Economists' dream or nightmare? Maximizing health gains from available resources using the NICE guidelines. |
| Q87023011 | Editorial statement on negative findings |
| Q34797274 | Effect of the implementation of an enterprise-wide Electronic Health Record on productivity in the Veterans Health Administration |
| Q83303973 | Effects of purchaser competition in the Dutch health system: is the glass half full or half empty? |
| Q40087494 | Efficiency improvements of public hospitals under a capitation payment scheme |
| Q82768123 | Eliminating drug price differentials across government programmes in the USA |
| Q81657175 | Emerging health care reform issues in the US presidential debate |
| Q45159489 | Empirically evaluating the impact of adjudicative tribunals in the health sector: context, challenges and opportunities |
| Q45832904 | Employer-provided health insurance and hospital mergers |
| Q47949236 | End-of-life care for patients with dementia in the United States: institutional realities |
| Q45003925 | Equity in Irish health care financing: measurement issues |
| Q40316765 | Equity in health care financing in Portugal: findings from the Household Budget Survey 2010/2011. |
| Q85039646 | Equity in health care: the Irish perspective |
| Q39844511 | Estimating the cost of smoking to the NHS in England and the impact of declining prevalence |
| Q83117332 | European policymaking on the tobacco advertising ban: the importance of escape routes |
| Q38874942 | Evaluating integrated healthcare for refugees and hosts in an African context |
| Q39534205 | Evidence and values: paying for end-of-life drugs in the British NHS. |
| Q83117339 | Evolution of Taiwan's health care system |
| Q98512947 | Evolution of the determinants of unmet health care needs in a universal health care system: Canada, 2001-2014 |
| Q95333334 | Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law |
| Q50199866 | Expanding Canadian Medicare to include a national pharmaceutical benefit while controlling expenditures: possible lessons from Israel |
| Q50423607 | Expanding the breadth of Medicare: learning from Australia |
| Q39885865 | Explaining medical disputes in Chinese public hospitals: the doctor-patient relationship and its implications for health policy reforms |
| Q104103461 | Explaining system-level change in welfare governance: the role of policy indeterminacy and concatenations of social mechanisms |
| Q37392991 | Explicit incorporation of equity considerations into economic evaluation of public health interventions |
| Q89488131 | Exploring differences between private and public prices in the English care homes market |
| Q90221988 | Fairness in drug prices: do economists think differently from the public? |
| Q81657234 | Family history of chronic disease and participation in healthy behaviours |
| Q61826382 | Family networks and healthy behaviour: evidence from Nepal |
| Q41463871 | Financial impact of the GFC: health care spending across the OECD. |
| Q51888330 | Financial incentives and psychiatric services in Australia: an empirical analysis of three policy changes. |
| Q46261172 | Fiscal space for domestic funding of health and other social services. |
| Q47650899 | Framing the issue of ageing and health care spending in Canada, the United Kingdom and the United States |
| Q40278835 | Framing the tax and health nexus: a neglected aspect of public health concern. |
| Q91737069 | Frontiers of health policy research |
| Q48331311 | Funding pharmaceutical innovation through direct tax credits |
| Q57468304 | Gaining pounds by losing pounds: preferences for lifestyle interventions to reduce obesity |
| Q91699858 | Getting involved: the extent and impact of patient and public involvement in the Swedish health system |
| Q46023905 | Getting out what we put in: productivity of the English National Health Service. |
| Q83046256 | Global health challenges in the pharmaceutical world |
| Q36319280 | Global health financing and the need for a data revolution |
| Q39330053 | Global health financing towards 2030 and beyond |
| Q38404592 | Global public goods for health: weaknesses and opportunities in the global health system |
| Q64044583 | Global public-private partnerships against neglected diseases: building governance structures for effective outcomes |
| Q64124075 | HPV vaccine status and sexual behavior among young sexually-active women in the US: evidence from the National Health and Nutrition Examination Survey, 2007-2014 |
| Q46035621 | Has the time come for cost-effectiveness analysis in US health care? |
| Q87844711 | Health care and health innovation in Europe: regulating for public benefit or for commercial profit? |
| Q91102302 | Health care and the future of economic growth: exploring alternative perspectives |
| Q43688608 | Health care cost containment in Denmark and Norway: a question of relative professional status? |
| Q85929831 | Health care reform after the Supreme Court: even more known unknowns |
| Q81657307 | Health determinants, policy indeterminacy? |
| Q98215973 | Health economics and emergence from lockdown: the great big marginal analysis |
| Q81657173 | Health economics made easy: guiding the initiated and uninitiated |
| Q90996026 | Health economics methods for public health resource allocation: a qualitative interview study of decision makers from an English local authority |
| Q47889001 | Health equality, social justice and the poverty of autonomy |
| Q47990020 | Health financing seen from the global level: beyond the use of gross national income |
| Q50802693 | Health plan choice in the Netherlands: restrictive health plans preferred by young and healthy individuals. |
| Q81657336 | Health policy. Editorial |
| Q38909672 | Health reform in Finland: current proposals and unresolved challenges |
| Q56893917 | Health technology appraisal and the courts: accountability for reasonableness and the judicial model of procedural justice |
| Q94460692 | Health, federalism and the European Union: lessons from comparative federalism about the European Union |
| Q52810242 | Healthcare innovation and patent law's 'pharmaceutical privilege': is there a pharmaceutical privilege? And if so, should we remove it? |
| Q42627931 | Healthcare policy tools as determinants of health-system efficiency: evidence from the OECD. |
| Q44844489 | Heterogeneity in the smoking response to health shocks by out-of-pocket spending risk. |
| Q81657211 | Hospital cost differences and payment by results |
| Q51697350 | Hospital prices and market structure in the hospital and insurance industries. |
| Q84517515 | How can demography inform health policy? |
| Q39966190 | How does the pharmaceutical industry influence prescription? A qualitative study of provider payment incentives and drug remunerations in hospitals in Shanghai |
| Q56973804 | How health care regionalisation in Italy is widening the North-South gap |
| Q87148003 | Human Resources in Health Care Systems: Reflecting on 'Cross-National Comparisons of Human Resources for Health - what can we learn?' |
| Q47955549 | Identifying health system value dimensions: more than health gain? |
| Q54090132 | If it looks like a duck, swims like a duck, and quacks like a duck, it probably is a duck: black market medicine and privatization in Israel. |
| Q64931947 | Impact of the Spanish smoke-free laws on cigarette sales, 2000-2015: partial bans on smoking in public places failed and only a total tobacco ban worked. |
| Q88593605 | Impacts of the type of social health insurance on health service utilisation and expenditures: implications for a unified system in China |
| Q51952330 | Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden. |
| Q83953480 | Improvements in English National Health Service (NHS) productivity were driven by the rollout of choice and competition |
| Q38347939 | Improving productive efficiency in hospitals: findings from a review of the international evidence |
| Q81657194 | In defence of subjective well-being |
| Q48073727 | In search of real autonomy for fertility patients |
| Q38504603 | Incentives and models of governance |
| Q48182852 | Incentives, health promotion and equality |
| Q41330112 | Incentivising improvements in health care delivery |
| Q41465699 | Incentivising improvements in health care delivery: a response to Adam Oliver |
| Q38991124 | Income and the use of health care: an empirical study of Egypt and Lebanon |
| Q81657292 | Inconsistent objectives--reflections on some selective health care policy developments in Europe |
| Q49051564 | Individual responsibility for what? - a conceptual framework for exploring the suitability of private financing in a publicly funded health-care system |
| Q40459051 | Influence of provider mix and regulation on primary care services supplied to US patients. |
| Q45906130 | Informal payments for health care services in Russia: old issue in new realities. |
| Q47299689 | Informal payments for health care--the phenomenon and its context |
| Q86805805 | Information will be the key to successful implementation |
| Q37779359 | Information-oriented patients and physician career satisfaction: is there a link? |
| Q38690494 | Innovation, informed consent, health research and the Supreme Court: Montgomery v Lanarkshire - a brave new world? |
| Q41472895 | Instrumentality in health care: a response to Adam Oliver |
| Q90337734 | Integration vs separation in the provision of health care: 24 OECD countries compared |
| Q47650862 | Integration: the firm and the health care sector |
| Q84485929 | Invisible hand? More like post-modern mush |
| Q47568554 | Involving citizens in disinvestment decisions: what do health professionals think? Findings from a multi-method study in the English NHS. |
| Q57112007 | Is Canada odd? A comparison of European and Canadian approaches to choice and regulation of the public/private divide in health care |
| Q83294107 | Is it not time for health economists to rethink equity and access? |
| Q30572220 | Is patient satisfaction in primary care dependent on structural and organizational characteristics among providers? Findings based on data from the national patient survey in Sweden |
| Q47590796 | Is the incorporation of equity considerations into economic evaluation really so simple? A comment on Cookson, Drummond and Weatherly |
| Q87759911 | Is the pro-competition policy an effective solution for China's public hospital reform? |
| Q90768991 | Is universal and uniform health insurance better for China? Evidence from the perspective of supply-induced demand |
| Q48588906 | Lawsuit activity, defensive medicine, and small area variation: the case of Cesarean sections revisited |
| Q98215970 | Learning from health system reform trajectories in seven Canadian provinces |
| Q48594665 | Legal advocacy as a tool to advance Roma Health |
| Q53332702 | Legal and organisational innovation in the Italian pharmacy system: commercial vs public interest. |
| Q43926366 | Lessons from health financing reform in central and eastern Europe and the former Soviet Union |
| Q81657224 | Letter on Calum Paton's 'howl of rage' |
| Q88079740 | Looking forward to the next 70 years: from a National Ill-Health Service to a National Health System |
| Q87404859 | Making Fair Choices: a symposium |
| Q52652330 | Making and breaking a health service. |
| Q57253075 | Making fair choices on the path to universal health coverage: a précis |
| Q36419585 | Making governance work in the health care sector: evidence from a 'natural experiment' in Italy. |
| Q129401597 | Managed competition in Colombia: convergence of public and private insurance and delivery |
| Q83303985 | Managed competition in the Dutch health system: is there a realistic alternative? |
| Q87431120 | Market competition, ownership, payment systems and the performance of health care providers - a panel study among Finnish occupational health services providers |
| Q81657301 | Measuring the globalization of health services: a possible index of openness of country health sectors to trade |
| Q44185422 | Medicaid after the Supreme Court decision |
| Q51888327 | Medicaid policy changes in mental health care and their effect on mental health outcomes. |
| Q46287090 | Medical savings accounts: assessing their impact on efficiency, equity and financial protection in health care |
| Q49501610 | Medicare and the care of First Nations, Métis and Inuit |
| Q51888335 | Mental health reform: Europe at the cross-roads. |
| Q44971112 | Mental health service delivery in Ontario, Canada: how do policy legacies shape prospects for reform? |
| Q52315369 | Methods for the economic evaluation of changes to the organisation and delivery of health services: principal challenges and recommendations. |
| Q48294768 | Modernizing concepts of access and equity |
| Q44912550 | Money or mental health: the cost of alleviating psychological distress with monetary compensation versus psychological therapy |
| Q85929828 | Much ado about nothing: the US Supreme Court's rules on health reform |
| Q45905374 | NFIB vs Sebelius: the political expediency of the Roberts Court. |
| Q38020289 | NICE's social value judgements about equity in health and health care |
| Q51872891 | NICE's use of cost effectiveness as an exemplar of a deliberative process. |
| Q81657267 | NICE: a nightmare worth having? |
| Q99587156 | Necessity under construction - societal weighing rationality in the appraisal of health care technologies |
| Q36668252 | Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research? |
| Q83901668 | Negotiating reform at an arm's length from the state: Disease Management Programmes and the introduction of clinical standards in Germany |
| Q97419573 | Neither protective nor harmonized: the crossborder regulation of medical devices in the EU |
| Q49051610 | Neo-liberal economic practices and population health: a cross-national analysis, 1980-2004. |
| Q39934373 | New Zealand's Primary Health Care Strategy: early effects of the new financing and payment system for general practice and future challenges |
| Q86058693 | Not everything is black or white: commentary on Filc D and Cohen N, blurring the boundaries between public and private health care services as an alternative explanation for the emergence of black medicine: the Israeli case |
| Q88740014 | Not so sweet refrain: sugar-sweetened beverage taxes, industry opposition and harnessing the lessons learned from tobacco control legal challenges |
| Q47650907 | Nudging the obese: a UK-US consideration |
| Q50018954 | Nurses as change agents for a better future in health care: the politics of drift and dilution |
| Q44696433 | Nursing home performance in resident care in the United States: is it only a matter of for-profit versus not-for-profit? |
| Q46905146 | Nursing home prices and market structure: the effect of assisted living industry expansion |
| Q53542905 | Objections to the use of cost-effectiveness analysis in the US: reflecting on 'Has the time come for cost-effectiveness analysis in US health care?'. |
| Q41278766 | On the margins of health economics: a response to 'resolving NICE'S nasty dilemma'. |
| Q57152714 | On the socio-economic determinants of antenatal care utilization in Azerbaijan: evidence and policy implications for reforms |
| Q90560636 | Opening the black box of diagnosis-related groups (DRGs): unpacking the technical remuneration structure of the Dutch DRG system |
| Q43464258 | Optimising waiting: a view from the English National Health Service |
| Q39124893 | Optimism about the future |
| Q50273048 | Organizational innovations and health care decentralization: a perspective from Spain |
| Q39984553 | Out-of-pocket payments and community-wide health outcomes: an examination of influenza vaccination subsidies in Japan. |
| Q38850855 | Outsourcing day surgery to private for-profit hospitals: the price effects of competitive tendering |
| Q37973530 | Overcoming fragmentation in health care: chronic care in Austria, Germany and The Netherlands |
| Q93035936 | Paradigms in operation: explaining pharmaceutical benefit assessment outcomes in England and Germany |
| Q45769364 | Patient choice and access to primary physician services in Norway |
| Q50547917 | Patient empowerment and the introduction of hospital choice in Denmark and Norway. |
| Q48331297 | Patient reactions to hospital choice in Norway, Denmark, and Sweden |
| Q48201092 | Pay scheme preferences and health policy objectives |
| Q47235969 | Paying for hospital care: the experience with implementing activity-based funding in five European countries |
| Q81657220 | Payment by results: qualified ambition? |
| Q81657242 | Peering through a glass: darkly |
| Q47679509 | Performance management: the clinician's tale |
| Q56896604 | Personal responsibility in the NHS Constitution and the social determinants of health approach: competitive or complementary? |
| Q45147327 | Perspectives on the importance of interdisciplinarity |
| Q40172452 | Perspectives on the policy 'black box': a comparative case study of orthopaedics services in England. |
| Q37912288 | Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? |
| Q47550427 | Pharmaceutical policy reform in Canada: lessons from history |
| Q91021439 | Physicians' attitudes towards accelerated access to medicines |
| Q48876564 | Physicians' career satisfaction, quality of care and patients' trust: the role of community uninsurance |
| Q83046229 | Policy choice or economic fundamentals: what drives the public-private health expenditure balance in Canada? |
| Q43514830 | Political or dental power in private and public service provision: a study of municipal expenditures for child dental care |
| Q58610313 | Political party ambitions and type-2 diabetes policy in Brazil and Mexico |
| Q81657246 | Politics over economics, fist over hand |
| Q129487788 | Preconditions for efficiency and affordability in mixed health systems: are they fulfilled in the Australian public–private mix? |
| Q43822032 | Preferred providers and the credible commitment problem in health insurance: first experiences with the implementation of managed competition in the Dutch health care system. |
| Q42662449 | Prescription drug co-payments and cost-related medication underuse |
| Q98215974 | Preserving social equity in marketized primary care: strategies in Sweden |
| Q58623088 | Priority setting in health – a political economy perspective |
| Q64044186 | Product development partnerships (PDPs) for neglected diseases: considerations on governance |
| Q90512425 | Program design, implementation and performance: the case of social health insurance in India |
| Q89141892 | Projecting future demand for informal care among older people in China: the road towards a sustainable long-term care system |
| Q51772786 | Projecting shortages and surpluses of doctors and nurses in the OECD: what looms ahead. |
| Q81657317 | Public involvement policies in health: exploring their conceptual basis |
| Q87410251 | Public vs private administration of rural health insurance schemes: a comparative study in Zhejiang of China |
| Q50547911 | Public-Private Partnerships in the health sector: the Danish experience. |
| Q40069718 | Pursuing cost containment in a pluralistic payer environment: from the aftermath of Clinton's failure at health care reform to the Balanced Budget Act of 1997. |
| Q90463524 | Quality improvement in hospitals in the Russian Federation, 2000-2016: a systematic review |
| Q126790804 | Quality improvement in hospitals in the Russian Federation, 2000–2016: a systematic review – ADDENDUM |
| Q38992437 | Raising more domestic money for health: prospects for low- and middle-income countries |
| Q84448899 | Rationing in the fiscal ice age |
| Q90281234 | Re-thinking unmet need for health care: introducing a dynamic perspective |
| Q48050047 | Reasonable disagreement and the generally unacceptable: a philosophical analysis of Making Fair Choices. |
| Q42689946 | Reassessing catastrophic health-care payments with a Nigerian case study |
| Q87340464 | Reflecting on 'Acquisition and disclosure of genetic information under alternative policy regimes: an economic analysis' |
| Q50900935 | Reflecting on 'An economic model of social capital and health'. |
| Q87148224 | Reflecting on 'Are health problems systemic? Politics of access and choice under Beveridge and Bismarck systems' |
| Q87087398 | Reflecting on 'Choice policies in Northern European health systems' |
| Q87087224 | Reflecting on 'Equity in health care: the Irish perspective' |
| Q39235221 | Reflecting on 'European policymaking on the tobacco advertising ban: the importance of escape routes'. |
| Q48037070 | Reflecting on 'Health technology appraisal and the courts: accountability for reasonableness and the judicial model of procedural justice'. |
| Q86082064 | Reflecting on 'Measuring the globalization of health services: a possible index of openness of country health sector to trade' |
| Q87113123 | Reflecting on 'Supporting health systems in Europe: added value of EU actions?' |
| Q87129496 | Reflecting on 'The 2010 U.S. health care reform: approaching and avoiding how other countries finance health care' |
| Q87356644 | Reflecting on 'The complexity of governance change: reforming the governance of medical performance in Germany' |
| Q87129387 | Reflecting on 'The evaluation of lifestyle interventions in the Netherlands' |
| Q48041257 | Reflecting on 'Valuing lives and life years: anomalies, implications, and an alternative'. |
| Q86173207 | Reflecting on the UK government's health and social care act 2012: introduction |
| Q58622963 | Reflecting on ‘Analytical perspectives on performance-based management: an outline of theoretical assumptions in the existing literature’ |
| Q47235991 | Reflections on the evolution of health technology assessment in Europe |
| Q83901666 | Reforming medical governance in Europe. What is it about institutions? |
| Q51872892 | Regionalization versus competition in complex cancer surgery. |
| Q92808818 | Regulating private medical institutions: a case study of China |
| Q87844701 | Regulatory theory: commercially sustainable markets rely upon satisfying the public interest in obtaining credible goods |
| Q45324249 | Reimbursement systems, organisational forms and patient selection: evidence from day surgery in Norway |
| Q93265181 | Reinterpreting the health in all policies obligation in Article 168 TFEU: the first step towards making enforcement a realistic prospect |
| Q57132388 | Reputations count: why benchmarking performance is improving health care across the world |
| Q98944168 | Resilient Managed Competition during Pandemics: Lessons from the Italian experience during COVID-19 |
| Q57763863 | Response |
| Q47913515 | Response on reviews of 'Never again?'. |
| Q84485935 | Response to Hunter, Dixon and Saltman |
| Q93020383 | Response to Rudolf Klein |
| Q90706945 | Response to Stephen Birch |
| Q57253077 | Response to our critics |
| Q53041365 | Response: Is there a case for risk-based premiums in health care insurance? |
| Q53041368 | Response: The case for risk-based subsidies in public health insurance. |
| Q38567749 | Results of the market-oriented reform in the Netherlands: a review. |
| Q30362747 | Revisiting 'The clinic': ethical and policy challenges in U.S. community health centers. |
| Q47714225 | Rising inequality and the implications for the future of private insurance in Canada |
| Q83462914 | Risk adjustment and risk equalization: what needs to be done? |
| Q39003895 | Scoping the shape of an iceberg: the future of public involvement in heath policy: reflecting on 'Public involvement policies in health: exploring their conceptual basis'. |
| Q50614506 | Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. |
| Q48369631 | Setting priorities in and for end-of-life care: challenges in the application of economic evaluation |
| Q88359665 | Seventy years of the British National Health Service: problem, politics and policy streams |
| Q47226289 | Shall we dance? The intricate project of comparison in the study of health policy |
| Q58190985 | Shaping the future of humankind: three commentaries on the ethics of enhancement |
| Q90004139 | Shifting threats and rhetoric: how Republican governors framed Medicaid expansion |
| Q42691454 | Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. |
| Q91282291 | Should performance-based incentives be used to motivate health care providers? Views of health sector managers in Cambodia, China and Pakistan |
| Q57783288 | Should prospective payments be differentiated for public and private healthcare providers? |
| Q47913527 | Sleepwalking into a political fiasco |
| Q83046236 | Small area variations and welfare loss in the use of outpatient antibiotics |
| Q87280144 | Smoking outside: the effect of the Irish workplace smoking ban on smoking prevalence among the employed |
| Q89169164 | Smoking, health and academic outcomes: evidence from a limited smoking campus policy |
| Q39029531 | Social capital and self-reported general and mental health in nine Former Soviet Union countries |
| Q47656580 | Social capital and the social formation of health-related preferences and behaviours |
| Q45408369 | Social capital, economics, and health: new evidence |
| Q88593609 | Social preferences for prioritising the treatment of disabled and chronically ill patients: beyond the order effect |
| Q47579991 | Social preferences for the inclusion of indirect benefits in the evaluation of publicly funded health services: results from an Australian survey |
| Q57150141 | Socioeconomic status and child health: what is the role of health care, health conditions, injuries and maternal health? |
| Q46478394 | Solidarity in competitive health insurance markets: analysing the relevant EC legal framework |
| Q44284278 | Some pain, no gain: experiences with the no-claim rebate in the Dutch health care system |
| Q49852982 | Space, place and (waiting) time: reflections on health policy and politics |
| Q81657205 | Specialization and physician-ownership in the US hospital industry: beyond the moratorium |
| Q94460714 | State strategies to address medicaid prescription spending: negotiated pricing vs price transparency |
| Q48369625 | Stealing on insensibly: end of life politics in the United States |
| Q53115103 | Still waiting for the great leap forward. |
| Q38235636 | Structural patterns in Swedish health policy: a 30-year perspective |
| Q37219018 | Structure and logic of regulation and governance of quality of health care: was OFSTED a model for the Commission for Health Improvement? |
| Q37219013 | Supplementary health insurance as a tool for risk-selection in mandatory basic health insurance markets. |
| Q49797915 | Supplementary physicians' fees: a sustainable system? |
| Q38130727 | Supporting health systems in Europe: added value of EU actions? |
| Q40738368 | Switching rates in health insurance markets decrease with age: empirical evidence and policy implications from the Netherlands |
| Q37219006 | Systematic reviews--do they 'work' in informing decision-making around health inequalities? |
| Q81657239 | Taking the iron fist a little further |
| Q89980891 | The 'Netflix plus model': can subscription financing improve access to medicines in low- and middle-income countries? |
| Q43891862 | The 'healthy immigrant' effect: initial evidence for Ireland |
| Q47564487 | The 'long and lonely road': translating evidence into policy |
| Q47564482 | The 'long and lonely road': translating evidence into policy reply |
| Q87432088 | The 2010 U.S. health care reform: approaching and avoiding how other countries finance health care |
| Q44982409 | The Affordable Care Act and the Supreme Court: American health care reform inches forward despite dysfunctional political institutions and politics |
| Q81657276 | The American right-wing policy agenda |
| Q38892815 | The European Union Joint Procurement Agreement for cross-border health threats: what is the potential for this new mechanism of health system collaboration? |
| Q50146249 | The National Health Service (NHS) at 70: Bevan's double-edged legacy |
| Q88079745 | The National Health Service (NHS) at 70: some comparative reflections |
| Q90706941 | The National Health Service (NHS) in 'crisis': the role played by a shift from horizontal to vertical principles of equity |
| Q54064258 | The Norwegian National Council for Priority Setting in Health Care: decisions and justifications. |
| Q43633908 | The US Supreme Court decision on the constitutional legitimacy of the Affordable Care Act. |
| Q40099638 | The United States confronts Ebola: suasion, executive action and fragmentation |
| Q46897540 | The administrator's perspective |
| Q33347766 | The case against choice and competition |
| Q53041360 | The case for risk-based premiums in public health insurance. |
| Q38404562 | The challenge of middle-income countries to development assistance for health: recipients, funders, both or neither? |
| Q83987537 | The complexities of negotiating governance change: introducing managerialism in Italy |
| Q81657202 | The complexity of governance change: reforming the governance of medical performance in Germany |
| Q98192415 | The constitutional economics of the World Health Organization |
| Q42170882 | The crisis as catalyst for reframing health care policies in the European Union |
| Q51052517 | The determinants of defensive medicine practices in Belgium. |
| Q40913955 | The determinants of efficiency in the Canadian health care system |
| Q81657304 | The determinants of policy for population health |
| Q57127765 | The dilemma of knowledge use in political decision-making: National Guidelines in a Swedish priority-setting context |
| Q36132974 | The double-edged sword of corporatisation in the hospital sector: evidence from Indonesia |
| Q36997195 | The effect of medical malpractice liability on rate of referrals received by specialist physicians |
| Q38797580 | The effect of universal health insurance for children in Vietnam |
| Q47202381 | The effects of competition on premiums: using United Healthcare's 2015 entry into Affordable Care Act's marketplaces as an instrumental variable |
| Q36323515 | The effects of payments for pharmaceuticals: a systematic literature review |
| Q38809650 | The efficiency of the local health systems: investigating the roles of health administrations and health care providers |
| Q83548092 | The evaluation of lifestyle interventions in the Netherlands |
| Q50139757 | The experience of implementing choice at point of referral: a comparison of the Netherlands and England |
| Q47226307 | The folly of cross-country ranking exercises |
| Q38870945 | The future of Indian Health Services for native Americans in the United States: an analysis of policy options and recommendations |
| Q43881406 | The generic drug market in Japan: will it finally take off? |
| Q87455410 | The global financial crisis, health and health care |
| Q38347943 | The health effects of the global financial crisis: can we reconcile the differing views? A network analysis of literature across disciplines |
| Q81657295 | The hedgehog and the fox: Glouberman and Marmor on 'healthy public policy' |
| Q50106325 | The impact of Universal Health Coverage on health care consumption and risky behaviours: evidence from Thailand |
| Q43899578 | The impact of changes in county public health expenditures on general health in the population |
| Q83472088 | The impact of geographic market definition on the stringency of hospital merger control in Germany and the Netherlands |
| Q47899243 | The impact of health insurance on health services utilization and health outcomes in Vietnam |
| Q44326553 | The impact of pricing and patent expiration on demand for pharmaceuticals: an examination of the use of broad-spectrum antimicrobials |
| Q47555170 | The impact of slow economic growth on health sector reform: a cross-national perspective |
| Q91207275 | The implementation of European Union (EU) rules on cross-border care: moving towards convergence? |
| Q38673516 | The incidence of health financing in South Africa: findings from a recent data set. |
| Q50549552 | The interplay between central and sub-central levels: the development of a systemic standard based programme for governing medical performance in Denmark. |
| Q45851105 | The introduction of a targeted user-pays approach to funding high-level residential aged care in Australia: an empirical investigation of the impact on price |
| Q83046244 | The legal framework for health care quality assurance in Germany |
| Q46140238 | The medicalisation of health inequalities and the English NHS: the role of resource allocation. |
| Q86805811 | The path from nowhere? |
| Q81657227 | The political economy of Chinese health reform |
| Q47650877 | The political economy of rationing health care in England and the US: the 'accidental logics' of political settlements |
| Q39789576 | The politics of health-care reform in the Netherlands since 2006. |
| Q61716391 | The practice of markets in Dutch health care: are we drinking from the same glass? |
| Q44113387 | The private-public mix of healthcare: evidence from a decentralised NHS country |
| Q85201956 | The process of dying: whose business is it anyway? Reflecting on 'Stealing on insensibly: end-of-life politics in the United States' |
| Q50564955 | The reactions to macro-economic crises in Nordic health system policies: Denmark, Finland and Sweden, 1980-2013. |
| Q93129694 | The regulation of competition and procurement in the National Health Service 2015-2018: enduring hierarchical control and the limits of juridification |
| Q126856403 | The regulation of competition and procurement in the National Health Service 2015–2018: enduring hierarchical control and the limits of juridification – ADDENDUM |
| Q39428096 | The regulation of competition in the National Health Service (NHS): what difference has the Health and Social Care Act 2012 made? |
| Q92497991 | The reimbursement of new medical technologies in German inpatient care: What factors explain which hospitals receive innovation payments? |
| Q93148122 | The resolution process and the timing of settlement of medical malpractice claims |
| Q51812828 | The rise of pragmatism in state/market debate. |
| Q47235955 | The rise of the regulatory state in health care: a comparative analysis of The Netherlands, England and Italy |
| Q94460745 | The role of EU competition law in health care and the 'undertaking' concept |
| Q46578151 | The role of care home fees in the public costs and distributional effects of potential reforms to care home funding for older people in England |
| Q47226317 | The role of comparative health studies for policy learning |
| Q38260802 | The role of hospital payments in the adoption of new medical technologies: an international survey of current practice. |
| Q86691113 | The role of the payment vehicle in non-market valuations of a health care service: willingness-to-pay for an ambulance helicopter service |
| Q86580684 | The special interdisciplinary contribution of institutional economics |
| Q38754463 | The state of American health care: November 2016 to November 2020, a look forward |
| Q37592330 | The ten characteristics of the high-performing chronic care system |
| Q58185273 | The trade in human organs in Tamil Nadu: the anatomy of regulatory failure |
| Q47226301 | The unwritten rules of cross-national policy analysis |
| Q38670095 | Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe |
| Q89344103 | Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe - CORRIGENDUM |
| Q52298205 | Tobacco: a product like any other? |
| Q30061772 | Towards a coherent global framework for health financing: recommendations and recent developments |
| Q83046250 | Towards an alternative economics of health care |
| Q98780143 | Towards more comprehensive health law and policy research |
| Q47621234 | Transatlantic comparative health policy analyses: introduction |
| Q45331816 | Transformation of the US Veterans Health Administration |
| Q93035989 | Transforming health care: the policy and politics of service reconfiguration in the UK's four health systems |
| Q95941492 | Transforming health care: the policy and politics of service reconfiguration in the UK's four health systems - CORRIGENDUM |
| Q47178833 | Transparency in practice: Evidence from 'verification analyses' issued by the Polish Agency for Health Technology Assessment in 2012-2015. |
| Q88740026 | Trends in ageing and ageing-in-place and the future market for institutional care: scenarios and policy implications |
| Q43958731 | Trends in health and health inequalities among major states of India: assessing progress through convergence models |
| Q101162296 | Trump v. The ACA |
| Q84713402 | Two faces of patient safety and care quality: a Franco-American comparison |
| Q85224517 | US health care: the unwinnable war against death |
| Q51849282 | Understanding recent increases in chronic disease treatment rates: more disease or more detection? |
| Q58622967 | Universal health coverage and user charges |
| Q46407618 | Universal health coverage and user charges: response to commentaries |
| Q44494535 | User charges for health care services: some further thoughts |
| Q37590417 | User choice in European health systems: towards a systematic framework for analysis |
| Q84485940 | Value based pricing for NHS medicines: magic bullet, counterfeit treatment or the mixture as before? |
| Q47584893 | Value congruence in health care priority setting: social values, institutions and decisions in three countries |
| Q91800849 | Value-based provider payment: towards a theoretically preferred design |
| Q47563275 | Valuing end-of-life care in the United States: the case of new cancer drugs |
| Q81657188 | Valuing health properly |
| Q81657155 | Valuing lives and life years: anomalies, implications, and an alternative |
| Q81657237 | Visible hand or invisible fist? The new market and choice in the English NHS |
| Q124017174 | We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment |
| Q42637968 | What factors influence seniors' desire for choice among health insurance options? Survey results on the Medicare prescription drug benefit |
| Q42199857 | What is the public appetite for healthy eating policies? Evidence from a cross-European survey |
| Q30061774 | What level of domestic government health expenditure should we aspire to for universal health coverage? |
| Q82401407 | What needs to be done in contingent valuation: have Smith and Sach missed the boat? |
| Q49897189 | What should health insurance cover? A comparison of Israeli and US approaches to benefit design under national health reform |
| Q128035533 | What's the ideal World Health Organization (WHO)? |
| Q90732605 | When do people choose to be informed? Predictors of information-seeking in the choice of primary care provider in Sweden |
| Q53726858 | When health technology assessment is confidential and experts have no power: the case of Hungary. |
| Q45984136 | Who benefits from health services in South Africa? |
| Q91940536 | Who knows best? Older people's and practitioner contributions to understanding and preventing avoidable hospital admissions |
| Q81657230 | Who switches sickness funds in Israel? |
| Q47376414 | Who's afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic |
| Q93129688 | Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study |
| Q85334992 | Why healthcare providers merge |
| Q49794844 | Why policy needs history (and historians). |
| Q53295838 | Willingness to pay for alternative policies for patients with Alzheimer's Disease. |
| Q88970197 | Willingness to pay for improved public health care services in Saudi Arabia: a contingent valuation study among heads of Saudi households |
| Q39266971 | Worker replacement and cost-benefit analysis of life-saving health care programs, a precautionary note |
| Q98564491 | World-Beating? Testing Britain's Covid Response and Tracing the Explanation |